TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Phase 3 trial of obicetrapib found lower blood levels of the Alzheimer’s biomarker pTau-217 among 1,727 participants carrying the ApoE4 risk gene. The result does not show that the drug prevents or treats Alzheimer’s, and earlier statin trials did not demonstrate a cognitive benefit. A Phase 2b study is now testing whether obicetrapib changes Alzheimer’s biomarkers in people without symptoms.
A Phase 3 study of obicetrapib, an experimental cholesterol-lowering drug, found lower blood levels of the Alzheimer’s-associated biomarker pTau-217 in a subgroup of 1,727 participants carrying the ApoE4 risk gene. The finding has prompted further research, but it does not establish that lowering cholesterol can prevent or treat Alzheimer’s.
Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor developed by NewAmsterdam Pharma. The Phase 3 trial enrolled people with heart disease or a genetic form of high cholesterol. In the ApoE4 subgroup, the drug lowered blood pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. The report does not provide the size of the biomarker change or show that participants’ memory or thinking improved.
The company has begun a separate Phase 2b Alzheimer’s trial, enrolling its first participant. That study will test whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people with signs of the disease but no symptoms. Biomarker movement is not the same as evidence that a treatment preserves cognition, delays symptoms or prevents dementia.
Evidence on statins, the widely used cholesterol-lowering medicines, is mixed. A Danish electronic-health-record study of more than 130,000 people with Type 2 diabetes reported lower dementia risk among people who started statins earlier. But the study was observational, so it cannot show that statins caused the difference. Earlier randomized trials did not find that statins treated cognitive decline, and a trial in healthy adults over 70 did not find a dementia-prevention effect.
A Biomarker Signal, Not a Treatment Result
The result gives researchers a reason to test whether a cholesterol drug can affect Alzheimer’s-related biology, particularly in people with the ApoE4 gene. It does not yet give patients or clinicians evidence that obicetrapib prevents dementia, slows cognitive decline or treats established Alzheimer’s.
That distinction matters because blood biomarkers can help track biological changes, but their movement alone does not establish a meaningful benefit to patients. The ongoing trial will need to clarify whether the biomarker effect is reproducible and whether it relates to clinical outcomes. For now, the findings do not support starting or changing cholesterol medication specifically for Alzheimer’s.
cholesterol-lowering supplements for brain health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Cholesterol Drugs Are Being Revisited
Cholesterol in the blood and cholesterol in the brain are not interchangeable. The cholesterol molecule in blood is too large to cross into the brain, and researchers are studying whether disruptions in the brain’s own cholesterol metabolism contribute to Alzheimer’s. Statins lower blood cholesterol and are used to reduce cardiovascular risks, but they do not readily reach the brain, according to the report.
The ApoE4 gene is associated with increased Alzheimer’s and cardiovascular risk and also affects how the body processes cholesterol. In the Danish study, people with Type 2 diabetes who began statins promptly had a reported 15% lower dementia risk over a decade; those who started later had a reported 10% decrease. These are observational associations, not proof of cause and effect. The article also notes that a randomized trial in healthy adults older than 70 found no dementia-prevention effect.
“I’m of the opinion that our traditional way of treating cholesterol with statins is probably not going to work.”
— Dr. Heather Ferris, University of Virginia endocrinologist and scientist, speaking to Being Patient
As an affiliate, we earn on qualifying purchases.
What the Biomarker Cannot Show
The report does not state how large the pTau-217 reduction was, whether it led to changes in cognitive performance, or whether the finding applies beyond the ApoE4 subgroup. It also does not establish that obicetrapib’s effect on blood biomarkers reflects a change in Alzheimer’s disease inside the brain.
The Danish statin findings could be influenced by differences between people who do and do not take the medication. Knopman told Being Patient that statin users may be more medically informed and more likely to follow healthy behaviours, making the groups difficult to compare. Whether statins reduce dementia risk, and whether obicetrapib can affect symptoms or disease progression, remain unsettled.
Alzheimer's biomarker testing kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The Alzheimer’s Trial Will Test More
The next reported milestone is the ongoing Phase 2b study of obicetrapib. Researchers plan to assess whether one year of treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The report does not give a completion date or say that the trial is designed to show prevention of dementia or improved cognition.
Further clinical evidence would be needed before the drug could be considered an Alzheimer’s treatment. Until results clarify its effects, the biomarker finding is an early research signal rather than a reason to use cholesterol-lowering medication for Alzheimer’s outside its established indications.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does lowering cholesterol prevent Alzheimer’s?
That has not been established. Observational research has reported associations between statin use and lower dementia risk, but randomized trials described in the report did not show a dementia-prevention effect.
Did obicetrapib improve memory or thinking?
The reported Phase 3 finding was a reduction in blood pTau-217 among ApoE4 carriers. The source does not report improved memory, thinking or other cognitive outcomes.
What does the pTau-217 result mean?
pTau-217 is a blood biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A change in the biomarker may be scientifically relevant, but its significance for disease symptoms or progression is not yet known.
Should someone take a statin or obicetrapib to prevent Alzheimer’s?
The report does not support taking either drug specifically to prevent or treat Alzheimer’s. Statins are used for cardiovascular indications, while obicetrapib is being studied. People should discuss medication decisions with a qualified health professional.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
